Title:
前立腺がんの治療のための併用療法
Document Type and Number:
Japanese Patent JP7441214
Kind Code:
B2
Abstract:
The invention provides methods for treating prostate cancer, including metastatic castration-resistant prostate cancer, comprising administering to a subject in need thereof a BET bromodomain inhibitor in combination with a second agent.
More Like This:
| WO/2023/203174 | HETEROCYCLIC CULLIN RING UBIQUITIN LIGASE COMPOUNDS AND USES THEREOF |
| JP2003292485 | SULFONAMIDE DERIVATIVE |
| WO/2007/067506 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS |
Inventors:
Sara Christine Atwell
Eric Campo
Sanjay Lacotia
Eric Campo
Sanjay Lacotia
Application Number:
JP2021514070A
Publication Date:
February 29, 2024
Filing Date:
September 13, 2019
Export Citation:
Assignee:
Zenith Epigenetics Ltd.
International Classes:
A61K31/437; A61K31/4164; A61K31/4439; A61K31/58; A61K45/00; A61P15/00; A61P35/00; A61P43/00
Domestic Patent References:
| JP2016523259A |
Foreign References:
| US20180153867 | ||||
| WO2017216772A2 |
Other References:
https://www.zenithepigenetics.com/upload/media_element/47/01/2016-aacr-poster-final.pdf[検索日:2023年8月15日]
Mol Cancer Ther,2015年,14(12_Supplement_2),C86
https://www.zenithepigenetics.com/upload/media_element/36/01/2015-aacr-eortc-poster.pdf[検索日:2023年8月15日]
Cancer Discovery,2018年01月,pp.24-36
Adv. Therap.,2018年,1,1800104(9 pages)
Mol. Cancer Res,2016年,14(4),pp.324-331
Expert Opin Investig Drugs,2017年,26(12),pp.1391-1397
Cancer Res,2018年,78(13_Supplement),5793
Mol Cancer Ther,2015年,14(12_Supplement_2),C86
https://www.zenithepigenetics.com/upload/media_element/36/01/2015-aacr-eortc-poster.pdf[検索日:2023年8月15日]
Cancer Discovery,2018年01月,pp.24-36
Adv. Therap.,2018年,1,1800104(9 pages)
Mol. Cancer Res,2016年,14(4),pp.324-331
Expert Opin Investig Drugs,2017年,26(12),pp.1391-1397
Cancer Res,2018年,78(13_Supplement),5793
Attorney, Agent or Firm:
Norito Yamao
Sei Morimoto
Nobuhiko Akiyama
Sei Morimoto
Nobuhiko Akiyama